Fel'dblium I V, Vorob'eva N N, Nikolaeva A M, Borisova V N, Mel'nikov V A, Budanov M V, Iakovleva I A, Kaz'ianin A V, Pushkareva E V, Griaznov V N, Griaznova D V, Shalunova N V, Perelygina O V, Ozeretskovskiĭ N A, Bektimirov T A
State Medical Academy, Perm, Russia.
Zh Mikrobiol Epidemiol Immunobiol. 2001 Nov-Dec(6):50-2.
Bubo-M, the first Russian combined vaccine, was found to have low reactogenicity. The difference between the number of postvaccinal reactions in the group of children immunized with Bubo-M (25.9%) and those in the group of children who had been simultaneously injected into different sites of the body with ADS-M toxoid (adsorbed DT toxoid with reduced antigen content) and hepatitis B vaccine (26.7%) was not statistically significant. Following immunization a considerable increase in the level of diphtheria and tetanus antibodies (p < 0.005) was observed in all children (100%), the level of HBs antibodies in the group of children immunized with Bubo-M (the geometric mean titer: 13,721 IU/l) essentially exceeding that observed in the control group injected with ADS-M toxoid and hepatitis B vaccine (the geometric mean of the titer: 2,441 IU/l). Bubo-M was duly registered and allowed for industrial production and medical use.